²é¿´: 5279  |  »Ø¸´: 20
±¾Ìû²úÉú 2 ¸ö DRDEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

isaballa00

Í­³æ (СÓÐÃûÆø)

[ÇóÖú] Ô­ÁÏÒ©Ó븨ÁÏÏàÈÝÐÔʵÑé

ÏÖÔÚ×öһƬ¼Á£¬¸ù¾ÝCTDÒªÇó£¬ÒªÌṩ¸¨ÁÏÏàÈÝÐÔʵÑ飬Çë½Ì´ó¼Ò¾ßÌåÊÇÔõô²Ù×÷£¿
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÔÚÀíÏëÓëÏÖʵ¼äÅÇ»²£¬µÃ¹ýÇÒ¹ý¡£¡£¡£
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

peggywu

гæ (³õÈëÎÄ̳)

ÒýÓûØÌû:
4Â¥: Originally posted by dongliang09 at 2011-08-04 14:30:07:
ÒÔÏÂÊDzμÓANDAÅàѵʱµÄ×ÊÁÏ£¨Ã»·­Ò룩£¬½ö¹©²Î¿¼¡£
Excipient Compatibility¸¨ÁÏÏàÈÝÐÔÑо¿
Expectation in Pharmaceutical Development from regulatory bodies:
•To understand with which common ex ...

4Â¥ÇëÎÊ£¬Õâ¸öANDAµÄÅàѵ×ÊÁÏÖÐÓйØÏàÈÝÐÔµÄÑо¿µÄ£¬ÓÐûÓÐÔÚFDAµÄÏà¹Ø·¨¹æÖÐÓй涨»òÎÄÏ×£¬¾ÍÊÇÓÐûÓоßÌå±È½ÏȨÍþµÄ³ö´¦£¬ÆÈÇÐÐèÒª£¬Íû»Ø¸´£¬¸Ð¼¤²»¾¡À²£¡
9Â¥2012-02-13 10:12:53
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 21 ¸ö»Ø´ð

missjane

ľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï
zhychen2008(½ð±Ò+1, DRDEPI+1): ¸Ðл»ØÌû½»Á÷ 2011-08-04 16:57:44
isaballa00(½ð±Ò+1): 2011-08-08 15:08:42
Ö÷Ò©Ó븨ÁÏÏàÈÝÐÔÑо¿ÊÇ´¦·½Ç°Ñо¿¹¤×÷ÖеÄÒ»ÏîÖØÒªÄÚÈÝ¡£ÏàÈÝÐÔÑо¿µÄ¾ßÌåÊÔÑé·½·¨Ó¦¸ù¾ÝÖÆ¼ÁÆ·ÖֵľßÌåÇé¿öÈ·¶¨¡£ÀýÈç¶ÔÓÚ¿Ú·þ¹ÌÌåÖÆ¼Á£¬¿ÉÑ¡Èô¸ÉÖÖ¸¨ÁÏ£¬È縨ÁÏÓÃÁ¿½Ï´óµÄ£¨ÈçÌî³ä¼ÁµÈ£©£¬¿ÉÓÃÖ÷Ò©£º¸¨ÁÏ£½1£º5µÄ±ÈÀý»ìºÏ£¬ÈôÓÃÁ¿½ÏСµÄ£¨ÈçÈ󻬼ÁµÈ£©£¬ÔòÓÃÖ÷Ò©£º¸¨ÁÏ£½20£º1µÄ±ÈÀý»ìºÏ£¬È¡Ò»¶¨Á¿£¬°´Îȶ¨ÐÔÓ°ÏìÒòËØÊÔÑé·½·¨£¬·Ö±ðÔÚÇ¿¹â£¨4500¡À500Lux£©¡¢¸ßΣ¨60¡æ£©¡¢¸ßʪ£¨Ïà¶Ôʪ¶È90¡À5%£©µÄÌõ¼þÏ·ÅÖÃ10Ì죬ÓÃHPLC»òÆäËûÊÊÒ˵ķ½·¨¼ì²éº¬Á¿¼°ÓйØÎïÖÊ·ÅÖÃǰºóÓÐÎޱ仯£¬Í¬Ê±¹Û²ìÍâ¹Û¡¢É«ÔóµÈÒ©ÎïÐÔ×´µÄ±ä»¯¡£±ØÒªÊ±£¬¿ÉÓÃÔ­ÁÏÒ©ºÍ¸¨ÁÏ·Ö±ð×öƽÐжÔÕÕʵÑ飬ÒÔÅбðÊÇÔ­ÁÏÒ©±¾ÉíµÄ±ä»¯»¹ÊǸ¨ÁϵÄÓ°Ïì¡£
ѧϰʹÈ˽ø²½£¡
2Â¥2011-08-04 13:03:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

dongliang09

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï
zhychen2008(½ð±Ò+2): ¸Ðл»ØÌû½»Á÷ 2011-08-04 17:01:07
ÒÔÏÂÊDzμÓANDAÅàѵʱµÄ×ÊÁÏ£¨Ã»·­Ò룩£¬½ö¹©²Î¿¼¡£
Excipient Compatibility¸¨ÁÏÏàÈÝÐÔÑо¿
Expectation in Pharmaceutical Development from regulatory bodies:
•To understand with which common excipients the drug is compatible;
•To give a ranking order of the compatibility in each category ofexcipients;
•To lay foundation of formulation design for a compound
In generic world, excipients used in the product are known and the product is stable. But, API-compatibility study is still needed because source of excipients is different. Different source of an excipient may have different starting materials, different process, and different impurity profile, thus indicating a potential impact on API
¸¨ÁÏÏàÈÝÐÔÑо¿µÄʵÑéÉè¼Æ(1)
•Select excipients: >2 excipients in each category (e.g., filler, binder, disintergant, glidant, wetting agent, lubricant, coating materials);
•Ratio of API to excipient: similar to the common ratio in a formulation;
API:Filler: 1:10
API: Binder or disintegrant: 1:1
API: lubricant or glidant, or surfactant: 10:1
•Container/closure: scintillation vial/tight seal. 500 mg powders/vial.
•Storage conditions: Stressed! 40¡ãC/75% RH open/closed, 55-60¡ãC ambient humidity.
•Sampling time: Initial, 2 weeks, 4 weeks.
•Sample analysis: physical appearance and impurity
Other things to be considered:
1: API control must be prepared and tested in order to know the real compatibility problem under stressed conditions.
2: A second set of samples may be prepared in which 5% of water is added into the powder mixture. Double the work load☺
3:Stearicacid and Dicalciumphosphate at 40¡ã
¸¨ÁÏÏàÈÝÐÔÑо¿½á¹ûµÄ·ÖÎö
•To obtain possible quantitative relationships to excipient characteristics and interaction rates
•Physical change: caking, liquefaction, and odor or gas formation, discoloration (amines, sugars)
•Impurities: total level and individual level
existing peaks vsnew peaks.
•To give the ranking order: selection of ¡°relatively¡±good one over ¡°less¡±good in the formulation
4Â¥2011-08-04 14:30:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

rnyter960

ľ³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï
zhychen2008(½ð±Ò+1): ¶àл»ØÌû½»Á÷ 2011-08-04 17:01:14
ÖÆ¼Á°Ù¿ÆÈ«ÊéµÚ¶þ¾íƬ¼ÁÖÐÓÐÌáµ½£¬¿ÉÒÔ¿´¿´´ËÊé
5Â¥2011-08-04 14:38:55
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[½Ìʦ֮¼Ò] ÊÛSCI-T0PÎÄÕ£¬ÎÒ:8O.5.5.1.O.54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 ASdOkHsho7FD 2026-08-28 4/200 2026-08-29 04:06 by gy1nBQXYQJqL
[»ù½ðÉêÇë] ¹ú×ÔÈ»ÆÀÉóÒâ¼û +11 wangmingqi 2026-08-28 15/750 2026-08-29 00:17 by fangyl2005
[»ù½ðÉêÇë] ¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶Ó­ÌÖÂÛ (½ð±Ò+15) +13 ÇçÌì¼ÓÓÍ 2026-08-26 14/700 2026-08-28 18:36 by huagongfeihu
[»ù½ðÉêÇë] ÓÐûÓÐÈÔûÊÕµ½ÐÅÏ¢µÄ +3 µÂÉÐÖÐÐÐ 2026-08-27 3/150 2026-08-28 15:24 by rongshuxia
[½Ìʦ֮¼Ò] µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡ +8 ËÕ¶«ÆÂ¶þÊÀ 2026-08-23 8/400 2026-08-28 14:41 by lkforward
[»ù½ðÉêÇë] Ôõô²é°¡ +6 huang1991js 2026-08-26 6/300 2026-08-28 08:42 by winsaint
[»ù½ðÉêÇë] »ù½ðδÖУ¬ÕâÖÖ´ð¸´ÊÇÄ£°åÂ𣿠+5 zhaosm1982 2026-08-27 6/300 2026-08-27 16:00 by lfy8008
[ÎÄѧ·¼²ÝÔ°] ÃÎÏë +3 myrtle 2026-08-26 3/150 2026-08-27 10:01 by angelyueyi
[»ù½ðÉêÇë] 2026ÄêµÄ¹ú¼ÒÉç¿Æ»ù½ðÏîĿͨѶÆÀÉóµÄйæÔòÓëж¯Ïò¡¢ÐÂÌôÕ½ +7 process2012 2026-08-23 10/500 2026-08-26 19:23 by hmhminy
[»ù½ðÉêÇë] 2026Äê8ÔÂ25ÈÕ¹ú×ÔÈ»·Å°ñǰͻȻÊÕµ½ÁÐÈëÆÀÉóר¼ÒÓʼþ£¬ÓйØÏµÂ𣿠+25 ľˮ˼¶¹ 2026-08-25 28/1400 2026-08-26 14:53 by draco1987
[»ù½ðÉêÇë] ÄÜ·ñÍ˳ö²ÎÓëµÄÃæÉÏÏîÄ¿½â³ýÏÞÏî +23 koalala 2026-08-24 26/1300 2026-08-26 14:29 by ±¦±´³æ×Ó
[»ù½ðÉêÇë] ¹úºÏÀïÃæÄÜ¿´µ½ÁË +7 Ò»»³Ü°Çï 2026-08-26 7/350 2026-08-26 11:23 by zhaosm1982
[»ù½ðÉêÇë] ϵͳ½ø²»È¥ +4 yanglien 2026-08-26 5/250 2026-08-26 11:10 by wenfengw83
[»ù½ðÉêÇë] ½ñÌìÎñί»á¿ªÍêÁË£¬Ã÷Ìì³ö½á¹ûÂð +19 angus9576 2026-08-25 23/1150 2026-08-26 10:03 by zp519
[Ö°³¡ÈËÉú] ѧÉúײ¼û¸¨µ¼Ô±ËÍÍâÂô£¬µÚ¶þÌìÈ«°à¶¼³ÁĬÁË +3 ¾¨ÓãÈÚ½ð_Õã½­_É 2026-08-22 3/150 2026-08-26 09:01 by zzuzxg
[»ù½ðÉêÇë] Å£À´£¡Ã×À´£¡ÃæÀ´£¡ +8 beefly 2026-08-26 8/400 2026-08-26 08:37 by xuzhipiao
[»ù½ðÉêÇë] Ã÷ÌìÓ¦¸Ã¿É²éÁË£¡£¿ +6 chengyan1220 2026-08-23 6/300 2026-08-25 19:45 by zfd97
[»ù½ðÉêÇë] Èç¹û´Ë¿ÌÄãÕýÔÚΪ¹ú»ù¸Ðµ½½¹ÂÇ£¬²»·ÁÀ´ÌýÌýÕâÊס¶»ù½ðÖ®Íâ¡· +8 scalable 2026-08-24 8/400 2026-08-25 12:52 by jnhyjjm
[»ù½ðÉêÇë] ûÓÐÈκÎÏûÏ¢-ÊDz»ÊǾÍÁ¹ÁË +9 ͼÀ²Í¼À² 2026-08-24 10/500 2026-08-25 11:59 by ÄϺ£Ð¡¸ç
[½Ìʦ֮¼Ò] Ìø²ÛºóÔÚÑÐÏîÄ¿Ôõô°ì£¿ +5 ¼òµ¥»¯xn 2026-08-22 10/500 2026-08-23 12:38 by ¼òµ¥»¯xn
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û